Hologic (HOLX) director Nanaz Mohtashami receives 3,190 restricted stock units
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Hologic Inc. director Nanaz Mohtashami received an equity award in the form of restricted stock units. On the reported date, she acquired 3,190 RSUs at no cash cost, classified as a grant or award acquisition. Following this grant, she now holds 7,371 shares of common stock in direct ownership.
The footnotes explain that these RSUs will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and will be settled in shares of common stock on a one-for-one basis, linking director compensation directly to future stock performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Mohtashami Nanaz
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,190 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 7,371 shares (Direct)
Footnotes (1)
- Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock. Restricted stock units are settled in shares of common stock on a one-for-one basis.
FAQ
What insider transaction did Hologic (HOLX) report for Nanaz Mohtashami?
Hologic reported that director Nanaz Mohtashami acquired 3,190 restricted stock units as an equity award. These RSUs were granted at a price of $0.0000 per share and increased her directly owned common stock position to 7,371 shares after the transaction.
What type of award did Hologic (HOLX) grant to director Nanaz Mohtashami?
Hologic granted restricted stock units to director Nanaz Mohtashami, classified as a grant, award, or other acquisition under transaction code A. The award covers 3,190 RSUs that convert into common stock on a one-for-one basis when they are ultimately settled.
When do Nanaz Mohtashami’s Hologic (HOLX) restricted stock units vest?
The restricted stock units granted to Nanaz Mohtashami vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. At that time, the RSUs are scheduled to be settled in an equivalent number of Hologic common shares, aligning director incentives with long-term shareholder value.